Published by
Functional convergence of a germline-encoded neutralizing antibody response in rhesus macaques immunized with HCV envelope glycoproteins
CHEN ET AL., 2021. IMMUNITY 54(4): 781-796. Read more […]
Author: admin
Published by
Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies
MURIN ET AL. 2021. CELL REP 35(2). Read more […]
Published by
Brain-specific angiogenesis inhibitor 1 is expressed in the Myo/Nog cell lineage
GERHART ET AL. 2020. PLoSONE 15(7):e0234792. Read more […]
Published by
Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics
GILCHUK ET AL. 2020. NATURE BIOMED ENG 4:1030-1043. Read More […]
Published by
Context Therapeutics and Integral Molecular Enter Collaboration and License Deal for Novel Claudin 6 Antibodies for Gynecologic Cancer Therapeutic Program
PHILADELPHIA, PA—APRIL 8, 2021—Context Therapeutics, a clinical-stage women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and […]
Published by
MPA – Deorphaning antibody panels using the Membrane Proteome Array
A collaborator developed a library of monoclonal antibodies capable of distinguishing among several cell types by using a phenotypic screening approach. Read More […]
Published by
Integral Molecular Enables Rapid Resistance Testing of Vaccines and Drugs Against Emerging Coronavirus Variants
PHILADELPHIA — In response to the evolving COVID-19 pandemic, Integral Molecular has adapted its SARS-CoV-2 reporter virus particle (RVP) technology to reflect emerging virus […]
Published by
Integral Molecular Announces Best-in-Class Antibodies Against Complex Oncology Target Claudin 18.2
PHILADELPHIA – Integral Molecular, the leader in discovering antibodies against multipass membrane proteins, announces fully optimized, high-affinity lead monoclonal antibodies (MAbs) against Claudin 18.2 […]
Published by
Integral Molecular Partners with China’s Leading Preclinical CRO JOINN for Comprehensive Specificity Testing of Antibodies and CAR-T Therapeutics
PHILADELPHIA – JOINN Laboratories, China’s leading preclinical contract research organization (CRO), has partnered with Integral Molecular to provide researchers in China with rapid antibody […]
